
| Disease Domain | Count |
|---|---|
| Neoplasms | 4 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 4 |
| Top 5 Target | Count |
|---|---|
| TrkA(Nerve growth factor receptor Trk-A) | 4 |
Target |
Mechanism TrkA antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TrkA antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TrkA antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date19 Mar 2026 |
Sponsor / Collaborator |
Start Date18 Feb 2026 |
Sponsor / Collaborator |
Start Date16 Jan 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Compound 6i(The British University in Egypt (BUE)) ( TrkA ) | Neoplasms More | Preclinical |
Compound 6n(The British University in Egypt (BUE)) ( TrkA ) | Neoplasms More | Preclinical |
Compound 6b(The British University in Egypt (BUE)) ( TrkA ) | Neoplasms More | Preclinical |
Compound 6j(The British University in Egypt (BUE)) ( TrkA ) | Neoplasms More | Preclinical |





